/
LENZ
$5.76-$0.06 (-1.03%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$182.5M
31M shares
52-week range
$5.23 – $50.40
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.69%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $15.0M | $0 | $0 | $19.1M |
| Cost of revenue | $0 | $121.0K | $734.0K | $0 | $0 | $58.0K | $705.0K |
| Gross profit | $0 | −$121.0K | −$734.0K | $15.0M | $0 | −$58.0K | $18.4M |
| Gross margin | — | — | — | 100.0% | — | — | 96.3% |
| R&D | $0 | $9.1M | $37.9M | $21.1M | $59.5M | $29.8M | $18.7M |
| Operating income | −$29.0K | −$13.5M | −$60.4M | −$10.5M | −$72.4M | −$58.6M | −$91.1M |
| EBITDA | $142.9K | −$68.2M | −$70.0M | −$10.5M | −$70.1M | −$49.7M | −$81.3M |
| Net income | −$109.0K | −$68.4M | −$70.8M | −$10.8M | −$70.0M | −$49.8M | −$82.1M |
| Net margin | — | — | — | -72.1% | — | — | -430.3% |
| EPS (diluted) | -0.01 | -8.24 | -8.54 | -12.89 | -15.30 | -2.34 | -2.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19M | $-4.56 | $-5.50–$-3.51 | 6 |
| 2027 | $65M | $-3.47 | $-4.93–$-1.53 | 6 |
| 2028 | $135M | $-1.66 | $-4.09–$1.57 | 4 |
| 2029 | $264M | $1.41 | $0.46–$2.32 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.59
Price
$5.76
Implied downside
-55%
Peer comparison
LENZ Therapeutics, Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
www.lenz-tx.com- Employees
- 152
- IPO / List date
- Mar 22, 2024
- HQ
- SOLANA BEACH, CA
Held by traders on TradeandTell
No one on the platform currently holds LENZ.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 25,366 | $732.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-03-22 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded LENZ yet.
